New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - cefuroxime sodium 263mg equivalent to 250 mg cefuroxime;   - powder for injection - 250 mg - active: cefuroxime sodium 263mg equivalent to 250 mg cefuroxime   - cefuroxime-aft is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. indications include: · respiratory tract infections e.g. acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections.

New Zealand - English - Medsafe (Medicines Safety Authority)

aft pharmaceuticals ltd - cefuroxime sodium 789mg equivalent to 750 mg cefuroxime;   - powder for injection - 750 mg - active: cefuroxime sodium 789mg equivalent to 750 mg cefuroxime   - cefuroxime-aft is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. indications include: · respiratory tract infections e.g. acute and chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections.

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - cefuroxime as sodium salt - powder for solution or suspension for injection or infusion - cefuroxime as sodium salt 750 mg - cefuroxime - cefuroxime - cefuroxime -fresenius is indicated for the treatment of the infections listed below in adults and children, including neonates (from birth).• community acquired pneumonia• acute exacerbations of chronic bronchitis• complicated urinary tract infections, including pyelonephritis• soft-tissue infections: cellulitis, erysipelas and wound infections• intra-abdominal infections • prophylaxis against infection in gastrointestinal (including oesophageal), orthopaedic, cardiovascular, and gynaecological surgery (including caesarean section)• nose infections for example, sinusitis• septic arthritis

Israel - English - Ministry of Health

neopharm (israel) 1996 ltd - cefuroxime as sodium salt - powder for solution for inj/inf - cefuroxime as sodium salt 1500 mg - cefuroxime - cefuroxime - cefuroxime -fresenius is indicated for the treatment of the infections listed below in adults and children, including neonates (from birth).• community acquired pneumonia• acute exacerbations of chronic bronchitis• complicated urinary tract infections, including pyelonephritis• soft-tissue infections: cellulitis, erysipelas and wound infections• intra-abdominal infections • prophylaxis against infection in gastrointestinal (including oesophageal), orthopaedic, cardiovascular, and gynaecological surgery (including caesarean section)• nose infections for example, sinusitis• septic arthritis

United States - English - NLM (National Library of Medicine)

wg critical care, llc - cefuroxime sodium (unii: r8a7m9my61) (cefuroxime - unii:o1r9fj93ed) - cefuroxime for injection, usp is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: - lower respiratory tract infections, including pneumonia, caused by streptococcus pneumoniae, haemophilus influenzae (including ampicillin-resistant strains), klebsiella spp., staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), streptococcus pyogenes , and escherichia coli . - urinary tract infections caused by escherichia coli and klebsiella spp. - skin and skin structure infections caused by staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), streptococcus pyogenes , escherichia coli, klebsiella spp., and enterobacter spp. - septicemia caused by staphylococcus aureus (penicillinase- and non-penicillinase-producing strains), streptococcus pneumoniae, escherichia coli, haemophilus influenzae (including ampicillin-resistant strains), and klebsiella spp. - meningitis

Ireland - English - HPRA (Health Products Regulatory Authority)

fresenius kabi deutschland gmbh - cefuroxime sodium - powder for solution for injection/infusion - 750 milligram(s) - second-generation cephalosporins; cefuroxime

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - cefuroxime sodium 1577.8mg equivalent to cefuroxime 1500 mg - powder for injection - 1.5 g - active: cefuroxime sodium 1577.8mg equivalent to cefuroxime 1500 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - cefuroxime sodium 263mg equivalent to cefuroxime 250 mg - powder for injection - 250 mg - active: cefuroxime sodium 263mg equivalent to cefuroxime 250 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

novartis new zealand ltd - cefuroxime sodium 788.9mg equivalent to cefuroxime 750 mg - powder for injection - 750 mg - active: cefuroxime sodium 788.9mg equivalent to cefuroxime 750 mg

New Zealand - English - Medsafe (Medicines Safety Authority)

glaxosmithkline nz limited - cefuroxime sodium 789mg equivalent to 750 mg cefuroxime;  ;   - powder for injection - 750 mg - active: cefuroxime sodium 789mg equivalent to 750 mg cefuroxime     - cefuroxime is a bactericidal cephalosporin antibiotic which is resistant to most ?-lactamases and is active against a wide range of gram-positive and gram-negative organisms. it is indicated for the treatment of infections before the infecting organism has been identified or when caused by sensitive bacteria. susceptibility to cefuroxime sodium will vary with geography and time and local susceptibility data should be consulted where available. indications include - respiratory tract infections for example, acute exacerbation of chronic bronchitis, infected bronchiectasis, bacterial pneumonia, lung abscess and post-operative chest infections. - ear, nose and throat infections for example, sinusitis, tonsillitis, pharyngitis and otitis media. - urinary tract infections for example, acute and chronic pyelonephritis, cystitis and asymptomatic bacteriuria. - soft-tissue infections for example, cellulitis, erysipelas and wound infections. - bone and joint infections for example, osteomyelitis and septic arthritis. - obstetric and gynaecological infections, pelvic inflammatory diseases. - gonorrhoea particularly when penicillin is unsuitable. - other infections including septicaemia, meningitis and peritonitis. - prophylaxis against infection in abdominal, pelvic, orthopaedic, cardiac, pulmonary, oesophageal and vascular surgery where there is increased risk from infection.